

30 December 2025

## Hereditary Angioedema (HAE) & IG

I am writing to request the following information under the FOIA

### HAE:

1. In the past 3 months [latest 3 months available] how many patients have received the following treatments [for any disease]:

<b>Berinert (Human C1-esterase inhibitor)</b>	<5
<b>Cinryze (Human C1-esterase inhibitor)</b>	7
<b>Orladeyo (Berotralstat)</b>	<5
<b>Takhzyro (Lanadelumab)</b>	9
<b>Ruconest (Recombinant human C1-esterase inhibitor)</b>	<5
<b>Firazyr (Icatibant injection)</b>	<5
<b>Icatibant - any brand except Firazyr</b>	<5

**Use of <5 (less than five):** We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act, as the small numbers involved could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

### IG:

2. In the past 3 months how many patients have received the following treatment for any disease:

Product	No. patients July to September 2025
<b>Cutaquig 16.5%</b>	25
<b>Cuvitru</b>	33
<b>Gamunex 10%</b>	79
<b>HyQvia</b>	35
<b>Intratect 10%</b>	20
<b>Kiovig 10%</b>	46
<b>Octagam 10%</b>	9
<b>Panzyga</b>	53
<b>Xembify</b>	18
<b>Gamten</b>	<5

3. In the past 3 months, how many patients have received any immunoglobulin treatment for the following diseases:

<b>Primary immunodeficiency (PID)</b>	140
<b>Secondary immunodeficiency (SID)</b>	140
<b>Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)</b>	18